|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||377.418 g/mol g·mol−1|
|3D model (JSmol)|
Selurampanel (INN, code name BGG492) is a drug closely related to the quinoxalinedione series which acts as a competitive antagonist of the AMPA and kainate receptors and, as of 2015, is being investigated in clinical trials by Novartis for the treatment of epilepsy. It has also been studied in the acute treatment of migraine, and was found to produce some pain relief, but with a relatively high rate of side effects.
- Faught, Edward (2014). "BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy". Expert Opinion on Investigational Drugs. 23 (1): 107–113. doi:10.1517/13543784.2014.848854. ISSN 1354-3784.
- Belcastro, Vincenzo; Verrotti, Alberto (2015). "Novel Molecular Targets for Drug-Treatment of Epilepsy": 183–199. doi:10.1007/978-3-319-12283-0_10. Cite journal requires
- Hanada, Takahisa (2014). "The AMPA receptor as a therapeutic target in epilepsy: preclinical and clinical evidence". Journal of Receptor, Ligand and Channel Research: 39. doi:10.2147/JRLCR.S51475. ISSN 1178-699X.
- Gomez-Mancilla B, Brand R, Jürgens TP, et al. (February 2014). "Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks". Cephalalgia. 34 (2): 103–13. doi:10.1177/0333102413499648. PMID 23963355.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|